C Mallinckrodt - JoVE Visualize

Showing results (1-10 of 13) with videos related to

Pageof 2

Sort By:

Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians|November 20, 1997

A comparison of sevoflurane and isoflurane for short-term anesthesia in polecats (Mustela eversmanni)J S Gaynor, J Wimsatt, C Mallinckrodt, et al.

Calcified Tissue International|August 1, 1997

Bone mineral density of the skull in premenopausal womenA S Turner, J M Maillet, C Mallinckrodt, et al.

Nature|August 9, 2001

Anabolism. Low mechanical signals strengthen long bonesC Rubin, A S Turner, S Bain, et al.

Bone|March 8, 2002

Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical boneC Rubin, A S Turner, C Mallinckrodt, et al.

Journal of Veterinary Internal Medicine|December 10, 1999

Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acidsE A McNiel, G K Ogilvie, C Mallinckrodt, et al.

Maturitas|October 31, 2003

Central and peripheral temperature changes in sheep following ovariectomyJ M MacLeay, E Lehmer, R M Enns, et al.

Journal of Veterinary Pharmacology and Therapeutics|November 12, 1998

The effects of hyperoxia on the biosynthesis of cyclooxygenase products and haemodynamic response to nitric oxide synthase inhibition with L-NAME in endotoxaemic pigsP W Hellyer, B Wright, C Mallinckrodt, et al.

Therapeutic Innovation & Regulatory Science|September 21, 2018

Recent Developments in the Prevention and Treatment of Missing DataC Mallinckrodt, J Roger, C Chuang-Stein, et al.

The Journal of Prevention of Alzheimer'S Disease|June 25, 2023

'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsS P Dickson, A M Wessels, S A Dowsett, et al.

The British Journal of Dermatology|February 7, 2018

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.

Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:

Pageof 2

Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians|November 20, 1997

A comparison of sevoflurane and isoflurane for short-term anesthesia in polecats (Mustela eversmanni)J S Gaynor, J Wimsatt, C Mallinckrodt, et al.

Calcified Tissue International|August 1, 1997

Bone mineral density of the skull in premenopausal womenA S Turner, J M Maillet, C Mallinckrodt, et al.

Nature|August 9, 2001

Anabolism. Low mechanical signals strengthen long bonesC Rubin, A S Turner, S Bain, et al.

Bone|March 8, 2002

Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical boneC Rubin, A S Turner, C Mallinckrodt, et al.

Journal of Veterinary Internal Medicine|December 10, 1999

Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acidsE A McNiel, G K Ogilvie, C Mallinckrodt, et al.

Maturitas|October 31, 2003

Central and peripheral temperature changes in sheep following ovariectomyJ M MacLeay, E Lehmer, R M Enns, et al.

Journal of Veterinary Pharmacology and Therapeutics|November 12, 1998

The effects of hyperoxia on the biosynthesis of cyclooxygenase products and haemodynamic response to nitric oxide synthase inhibition with L-NAME in endotoxaemic pigsP W Hellyer, B Wright, C Mallinckrodt, et al.

Therapeutic Innovation & Regulatory Science|September 21, 2018

Recent Developments in the Prevention and Treatment of Missing DataC Mallinckrodt, J Roger, C Chuang-Stein, et al.

The Journal of Prevention of Alzheimer'S Disease|June 25, 2023

'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study FindingsS P Dickson, A M Wessels, S A Dowsett, et al.

The British Journal of Dermatology|February 7, 2018

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.

Pageof 2